A
Arnon Nagler
Researcher at Sheba Medical Center
Publications - 1435
Citations - 51740
Arnon Nagler is an academic researcher from Sheba Medical Center. The author has contributed to research in topics: Transplantation & Hematopoietic stem cell transplantation. The author has an hindex of 98, co-authored 1316 publications receiving 44298 citations. Previous affiliations of Arnon Nagler include French Institute of Health and Medical Research & University of Paris.
Papers
More filters
Journal ArticleDOI
The Role of Measurable Residual Disease (MRD) in Hematopoietic Stem Cell Transplantation for Hematological Malignancies Focusing on Acute Leukemia.
Anna Czyż,Arnon Nagler +1 more
TL;DR: There are still many open issues such as the role of additional pre-transplant consolidation for MRD eradication, the ability of HSCT to overcome negative influence of MRD positivity on survival, the impact of conditioning regimen intensity on MRD clearance post HSCT, and transplantation outcomes or the selection of optimal donor with regards to MRD status.
Journal ArticleDOI
Exome sequencing identifies germline variants in DIS3 in familial multiple myeloma.
Maroulio Pertesi,Maroulio Pertesi,Maxime Vallée,Xiaomu Wei,Maria Victoria Revuelta,Perrine Galia,Delphine Demangel,Javier Oliver,Javier Oliver,Matthieu Foll,Siwei Chen,Emeline Perrial,Emeline Perrial,Laurent Garderet,Laurent Garderet,Jill Corre,Xavier Leleu,Eileen M Boyle,Olivier Decaux,Olivier Decaux,Philippe Rodon,Brigitte Kolb,Borhane Slama,Philippe Mineur,Eric Voog,Catherine Le Bris,Jean Fontan,Michel Maigre,Marie Beaumont,Isabelle Azais,Hagay Sobol,Marguerite Vignon,Bruno Royer,Aurore Perrot,Jean Gabriel Fuzibet,Véronique Dorvaux,Bruno Anglaret,Pascale Cony-Makhoul,Christian Berthou,Florence Desquesnes,Brigitte Pegourie,Serge Leyvraz,Laurent Mosser,Nicole Frenkiel,Karine Augeul-Meunier,Isabelle Leduc,Cécile Leyronnas,Laurent Voillat,Philippe Casassus,Claire Mathiot,Nathalie Cheron,Etienne Paubelle,Philippe Moreau,Yves-Jean Bignon,Bertrand Joly,Pascal Bourquard,Denis Caillot,Hervé Naman,Sophie Rigaudeau,Gerald Marit,Margaret Macro,Isabelle Lambrecht,Manuel Cliquennois,Laure Vincent,Philippe Helias,Hervé Avet-Loiseau,Victor Moreno,Rui Manuel Reis,Judit Várkonyi,Marcin Kruszewski,Annette Juul Vangsted,Artur Jurczyszyn,Jan Maciej Zaucha,Juan Sainz,Malgorzata Krawczyk-Kulis,Marzena Wątek,Matteo Pelosini,Elżbieta Iskierka-Jażdżewska,Norbert Grząśko,Joaquin Martinez-Lopez,Andres Jerez,Daniele Campa,Gabriele Buda,Fabienne Lesueur,Marek Dudziński,Ramón García-Sanz,Arnon Nagler,Marcin Rymko,Krzysztof Jamroziak,Aleksandra Butrym,Federico Canzian,Ofure Obazee,Björn Nilsson,Robert J. Klein,Steven M. Lipkin,James D. McKay,Charles Dumontet +96 more
TL;DR: Exome sequencing identifies germline variants in DIS3 in familial multiple myeloma Maroulio Pertesi, Maxime Vallée, Xiaomu Wei, Maria Revuelta, Perrine Galia, Delphine Demangel, Victor Oliver, Matthieu Foll, Siwei Chen, Emeline Perrial, et al.
Journal ArticleDOI
A phase I study of INNO-406 in patients with advanced Philadelphia chromosome-positive (Ph+) leukemias who are resistant or intolerant to imatinib and may have also failed second-generation tyrosine kinase inhibitors
Javier Pinilla-Ibarz,Hagop M. Kantarjian,J. E. Cortes,P. le Coutre,Arnon Nagler,A. Hochhaus,D. Jones,Shinya Kimura,J. Giampalmi,L. Gleich,Oliver G. Ottmann +10 more
TL;DR: In this paper, an oral dual Abl/Lyn kinase inhibitor, called INNO-406, which is up to 55 times more potent than imatinib (I), was presented.
Journal ArticleDOI
VANTAGE 095: An International, Multicenter, Open-Label Study of Vorinostat (MK-0683) in Combination With Bortezomib in Patients With Relapsed and Refractory Multiple Myeloma
David S. Siegel,Meletios A. Dimopoulos,Sundar Jagannath,Hartmut Goldschmidt,Simon Durrant,Jonathan L. Kaufman,Xavier Leleu,Arnon Nagler,Fritz Offner,Thorsten Graef,Joseph E. Eid,Jennifer Houp,Christine K. Gause,Scott Vuocolo,Kenneth C. Anderson +14 more
TL;DR: The combination of vorinostat and bortezomib is active in patients with multiple myeloma refractory to novel treatment modalities and offers a new therapeutic option for this difficult-to-treat patient population.
Journal ArticleDOI
CAR-T cells: the narrow path between hope and bankruptcy?
Christian Chabannon,J. Kuball,Eoin McGrath,Peter Bader,Carlo Dufour,A.C. Lankester,Grzegorz W. Basak,Silvia Montoto,Arnon Nagler,John A. Snowden,Jan Styczyński,Rafael F. Duarte,Nicolaus Kröger,M. Mohty +13 more
TL;DR: Clinical activity in the field of CAR-T cells remains relatively modest across member states and neighbouring countries, with many academic centres waiting for approval of their participation as co-investigators in industrysponsored trials, and relatively few biotech companies originating from the scientific community established on the authors' continent.